Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.

Citation data:

British journal of haematology, ISSN: 1365-2141, Vol: 173, Issue: 4, Page: 597-616

Publication Year:
Usage 64
Abstract Views 60
Link-outs 4
Captures 14
Readers 14
Social Media 4
Tweets 4
Citations 4
Citation Indexes 4
Repository URL:
Mitch Cairo; Ross Pinkerton; Matthew J. Barth; Yaya Chu; Patrick J. Hanley; Mitchell S. Cairo
Medicine; Pediatrics
Most Recent Tweet View All Tweets
review description
With the introduction of the anti-CD20 monoclonal antibody rituximab, B-cell non-Hodgkin lymphoma was the first malignancy successfully treated with an immunotherapeutic agent. Since then, numerous advances have expanded the repertoire of immunotherapeutic agents available for the treatment of a variety of malignancies, including many lymphoma subtypes. These include the introduction of monoclonal antibodies targeting a variety of cell surface proteins, including the successful targeting of immunoregulatory checkpoint receptors present on T-cells or tumour cells. Additionally, cellular immunotherapeutic approaches utilize T- or Natural Killer-cells generated with chimeric antigen receptors against cell surface proteins or Epstein-Barr virus-associated latent membrane proteins. The following review describes the current state of immunotherapy for non-Hodgkin lymphoma including a summary of currently available data and promising agents currently in clinical development with future promise in the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.